471 Association of Antidepressant Timing and Dose on Overall Survival in Patients With Glioblastoma

View at publisher Summarise with VIRAT
Authors: Asha Krishnakumar, Ashwin Ghadiyaram, Alper Dincer, Yue H. Zhang, Charles F. Opalak, William C. Broaddus
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Depression is a common comorbidity in patients with glioblastoma multiforme. Antidepressants, which can cross the blood-brain barrier, are commonly prescribed in this patient population and have been shown to have anti-tumor effects in preclinical studies. However, clinical studies demonstrate an inconsistent outcome in this patient population. METHODS: This retrospective study was conducted with patients presenting with glioblastoma between January 2005 and April 2018. Cox proportional hazards model regressions were performed on timing, dosing, and class of antidepressants to determine the association between these factors and overall survival. RESULTS: This study had a total of 217 patients, with 83 (38.2%) being prescribed an antidepressant. A history of depression or anxiety was associated with an increased mortality risk (HR = 1.70 [1.10-2.65]; p = 0.018). Using versus not using an antidepressant (HR = 1.16 [0.86-1.55]; p = 0.33), or using SSRIs versus SNRIs/TCAs, had no statistically significant difference in mortality risk (HR = 1.10 [0.66-1.83]; p=0.71). Initiating antidepressants a longer time interval after cancer treatment was associated with a decreased risk of death (HR = 0.94 [0.91-0.96]; p < 0.0001), whereas starting an antidepressant before initiating cancer treatment was associated with a higher risk of death (HR = 1.93 [1.13-3.28]; p = 0.016). CONCLUSIONS: Initiating antidepressants both before glioblastoma diagnosis and glioblastoma treatment was significantly associated with a decreased overall survival in patients with glioblastoma. Initiation of antidepressants after glioblastoma treatment was significantly associated with an increased overall survival. These findings may be explained either as a direct result of the antidepressant as a potential adjuvant therapeutic for glioblastoma, and by the idea of how preexisting depression can confer an increased mortality risk for glioblastoma patients at baseline. Further study can better elucidate the clinical effects of antidepressants on overall survival in patients with glioblastoma.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Cancer survivorship and care Cancer Stress Anesthesia and Immune Response

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
138–138
Publication date
26 March 2026
Language
EN